Roche Loss on Avastin Appeal Is Third in a Row at FDA Panel

Roche Holding AG’s failure to persuade a U.S. panel to back Avastin in breast cancer is the third such loss for the Swiss drugmaker as it looks for new ways to expand sales of the world’s top-selling cancer medicine.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.